Beschreibung
Carbohydrate-Based Therapeutics Comprehensive resource summarizing opportunities and latest progress in design methodologies for carbohydrate-based therapeutics through a disease-oriented approach CarbohydrateBased Therapeutics covers current progress and explores new frontiers in carbohydratebased therapeutic applications, utilizing a unique approach by providing a detailed background of diseases coupled with subsequent carbohydrate-based therapies. The link between chemistry and design of novel carbohydrate-based medicines is highlighted and a broad overview of all the potential applications of carbohydrates is given. Emphasis is laid on concepts used for carbohydrate drug design, structure? activity relationship, and impact on health and diseases. The text also discusses newer topics like nanoparticles, material science, and tissue generation. CarbohydrateBased Therapeutics includes information on: * Antimicrobial carbohydrate-based therapies, covering antibacterial and antiviral vaccines, antifungal therapies, anti-influenza therapeutics, and antiadhesive carbohydrates and glycomimetics * Anticancer carbohydratebased therapies, covering cancer vaccines and immunotherapy, and carbohydrate tools in cancer biology * Carbohydrate-based therapies in metabolic, neuronal, and immune disorders, covering carbohydrate-based therapeutics for lysosomal disorders and neurodegenerative diseases * New frontiers in carbohydrate-based therapies, covering carbohydrates for tissue engineering, antiangiogenic and regenerative medicine Providing comprehensive coverage of foundational knowledge on the subject in a unique and highly accessible format while also exploring the state of the art in the field?s applications, Carbohydrate-Based Therapeutics is an essential resource for medicinal, pharmaceutical, and organic chemists, chemists in industry, biochemists, and biotechnologists.
Autorenporträt
Roberto Adamo joined Novartis Vaccines in 2007 where he was later appointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the Conjugation & Synthesis Platform. After the GSK acquisition of the company he became Preclinical Representative Leader of the Conjugation Platform. He is currently Technology and Project Leader at GSK, Italy. His research focuses on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics. He has over 70 publications in the field including a book. He is the Associate editor of the Glycoconjugate Journal. Luigi Lay is full professor at the Department of Chemistry of the University of Milan. His research interests are focused on carbohydrate chemistry and the use of synthetic glycans to investigate their biological properties. He is author of 86 publications in the field and some book chapters.
Herstellerkennzeichnung:
Wiley-VCH GmbH
Boschstrasse 12
69469 Weinheim
DE
E-Mail: product_safety@wiley.com
